How many drugs treat Osteosarcoma of bone?

Drug Landscape tracks 9 marketed treatments for Osteosarcoma of bone (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/osteosarcoma-of-bone.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Osteosarcoma of bone — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteosarcoma of bone (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteosarcoma of bone, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mepact	MIFAMURTIDE	Takeda France SAS	mifamurtide	Nucleotide-binding oligomerization domain-containing protein 2	2009-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Trexall	methotrexate	Generic (originally Lederle Laboratories)	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Methotrexat	Methotrexat	Biocad		Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4
Hydroxydaunomycin	Hydroxydaunomycin	Weill Medical College of Cornell University		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunorubicin	Hydroxydaunorubicin	University of Colorado, Denver		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
adriacin	adriacin	Chipscreen Biosciences, Ltd.		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Osteosarcoma of bone
Chipscreen Biosciences, Ltd. · 1 drug in Osteosarcoma of bone
Generic (originally Lederle Laboratories) · 1 drug in Osteosarcoma of bone
Johann Wolfgang Goethe University Hospital · 1 drug in Osteosarcoma of bone
Takeda France SAS · 1 drug in Osteosarcoma of bone
University of Colorado, Denver · 1 drug in Osteosarcoma of bone
Biocad · 1 drug in Osteosarcoma of bone
Weill Medical College of Cornell University · 1 drug in Osteosarcoma of bone

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteosarcoma of bone:

Cite this brief

Drug Landscape (2026). Osteosarcoma of bone — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteosarcoma-of-bone. Accessed 2026-06-10.

Osteosarcoma of bone full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing